7738 Journal of Medicinal Chemistry, 2006, Vol. 49, No. 26
Doshi et al.
(19) Chan, S. L.; Lee, M. C.; Tan, K. O.; Yang, L.; Lee, A. S. Y.; Flotow,
H.; Fu, N. Y.; Butler, M. S.; Soejarto, D. D.; Buss, A. D.; Yu, V. C.
Identification of chelerythrine as an inhibitor of BclXL function. J.
Biol. Chem. 2003, 278, 20453-20456.
(20) Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X.; Cao, Y.;
Guo, R.; Li, B.; Zhu, X.; Huang, Y.; Long, Y.; Roller, P. P.; Yang,
D.; Wang, S. Discovery of small-molecule inhibitors of Bcl-2 through
structure-based computer screening. J. Med. Chem. 2001, 44, 4313-
4324.
encoding Bcl-w∆C22 or DNA sequence encoding Bcl-
XL∆loop∆C40 inserted. We also thank Dr. Daniel Johnson at
the University of Pittsburgh for providing Bcl-XL overexpressing
Jurkat cells and Dr. Claus Belka at University of Tuebingen
for providing the Bcl-2 overexpressing Jurkat cells.
Supporting Information Available: The SDS-PAGE char-
acterization of recombinant Bcl-2, Bcl-XL, and Bcl-w proteins; dose
response curves of the in vitro cytotoxicity of some compounds in
three Jurkat cells; dose response curves of the in vitro cytotoxicities
of 1 and its analogues against NCI-H460 cells; the correlation of
the binding affinities to the in vitro cytotoxicities of the compounds
in NCI-H460 cells; the mathematical derivations of the equation
for the calculation of Ki based on the fluorescence polarization
single-site competition binding assay; and X-ray crystallographic
data for 3a. This material is available free of charge via the Internet
(21) Mihara, M.; Erster, S.; Zaika, A.; Petrenko, O.; Chittenden, T.;
Pancoska, P.; Moll, U. M. p53 has a direct apoptogenic role at the
mitochondria. Mol. Cell 2003, 11, 577-590.
(22) Real, P. J.; Cao, Y.; Wang, R.; Nikolovska-Coleska, Z.; Sanz-Ortiz,
J.; Wang, S.; Fernandez-Luna, J. L. Breast cancer cells can evade
apoptosis-mediated selective killing by a novel small molecule
inhibitor of Bcl-2. Cancer Res. 2004, 64, 7947-7953.
(23) Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.;
Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges,
J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer,
A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. J.; Ng, S.;
Nimmer, P. M.; O’Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed,
J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.;
Wang, B.; Wendt, M. B.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.
An inhibitor of Bcl-2 family proteins induces regression of solid
tumours. Nature 2005, 435, 677-681.
(24) Gemperli, A. C.; Rutledge, S. E.; Maranda, A.; Schepartz, A. Paralog-
selective ligands for Bcl-2 proteins. J. Am. Chem. Soc. 2005, 127,
1596-1597.
(25) Lickliter, J. D.; Nood, N. J.; Johnson, L.; McHugh, G.; Tan, J.; Wood,
F.; Cox, J.; Wickham, N. W. HA14-1. selectively induces
apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and
enhances cytarabine-induced cell death. Leukemia 2003, 17, 2074-
2080.
(26) Dai, Y.; Rahmani, M.; Corey, S. J.; Dent, P.; Grant, S. A Bcr/Abl-
independent, Lyn-dependent form of imatinib mesylate (STI-571)
resistance is associated with altered expression of Bcl-2. J. Biol.
Chem. 2004, 279, 34227-34239.
(27) Yamaguchi, H.; Paranawithana, S. R.; Lee, M. W.; Huang, Z.; Bhalla,
K. N.; Wang, H. Epothilone B analogue (BMS-247550)-mediated
cytotoxicity through induction of bax conformational change in
human breast cancer cells. Cancer Res. 2002, 62, 466-471.
(28) Pei, X.; Dai, Y.; Grant, S. The proteasome inhibitor bortezomib
promotes mitochondrial injury and apoptosis induced by the small
molecule Bcl-2 inhibitor HA14-1. in multiple myeloma cells.
Leukemia 2003, 17, 2036-2045.
(29) Sinicrope, F. A.; Penington, R. C.; Tang, X. M. Tumor necrosis factor-
related apoptosis-inducing ligand-induced apoptosis is inhibited by
Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1,
in human colon cancer cells. Clin. Cancer Res. 2004, 10, 8284-
8292.
(30) Hao, J.; Yu, M.; Liu, F.; Newland, A. C.; Jia, L. Bcl-2
inhibitors sensitize tumor necrosis factor-related apoptosis-
inducing ligand-induced apoptosis by uncoupling of mitochondrial
respiration in human leukemic CEM cells. Cancer Res. 2004, 64,
3607-3616.
(31) Sutter, A. P.; Maaser, K.; Grabowski, P.; Bradacs, G.; Vormbrock,
K.; Ho¨pfner, M.; Krahn, A.; Heine, B.; Stein, H.; Somasundaram,
R.; Schuppan, D.; Zeitz, M.; Scheru¨bl, H. Peripheral benzodiazepine
receptor ligands induce apoptosis and cell cycle arrest in human
hepatocellular carcinoma cells and enhance chemosensitivity to
paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
J. Hepatol. 2004, 41, 799-807.
(32) Nimmanapalli, R.; O’Bryan, E.; Kuhn, D.; Yamaguchi, H.; Wang,
H.; Bhalla, K. N. Regulation of 17-AAG-induced apoptosis: role of
Bcl-2, Bcl-xL, and Bax downstream of 17-AAG-mediated down-
regulation of Akt, Raf-1, and Src kinases. Blood 2003, 102, 269-
275.
(33) Pei, X.; Dai, Y.; Grant, S. The small-molecule Bcl-2 inhibitor HA14-1
interacts synergistically with flavopiridol to induce mitochondrial
injury and apoptosis in human myeloma cells through a free radical-
dependent and Jun NH2-terminal kinase-dependent mechanism. Mol.
Cancer Ther. 2004, 3, 1513-1524.
(34) Skommer, J.; Wlodkowic, D.; Ma¨tto¨, M.; Eray, M.; Pelkonen, J.
HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and
modulates action of selected anticancer drugs in follicular lymphoma
B cells. Leuk. Res. 2006, 20, 322-331.
References
(1) Pinedo, H. M.; Giaccone, G. Drug Resistance in the Treatment of
Cancer; Cambridge University Press: Cambridge, U.K., 1998; pp
199-208.
(2) Kiechle, F. L.; Zhang, X. Apoptosis: biochemical aspects and clinical
implications. Clin. Chim. Acta 2002, 326, 27-45.
(3) Folkman, J. Angiogenesis and apoptosis. Semin. Cancer Biol. 2003,
13, 159-167.
(4) Reinhold, W. C.; Kouros-Mehr, H.; Kohn, K. W.; Maunakea, A. K.;
Lababidi, S.; Roschke, A.; Stover, K.; Alexander, J.; Pantazis, P.;
Miller, L.; Liu, E.; Kirsch, I. R.; Urasaki, Y.; Pommier, Y.; Weinstein,
J. N. Apoptotic susceptibility of cancer cells selected for camptothecin
resistance: gene expression profiling, functional analysis, and
molecular interaction mapping. Cancer Res. 2003, 63, 1000-1011.
(5) Genta. Proportion of Patients Who at the Time of Diagnosis
Overexpress Bcl-2 Relative to a Normal Cellular Population. http://
(6) Kim, R.; Tanabe, K.; Emi, M.; Uchida, Y.; Toge, T. Modulation of
tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast
carcinoma cells. Cancer 2005, 103, 2199-2207.
(7) Kim, R.; Emi, M.; Tanabe, K.; Uchida, Y.; Toge, T. Therapeutic
potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
Cancer 2004, 101, 2491-2502.
(8) Tanabe, K.; Kim, R.; Inoue, H.; Emi, M.; Uchida, Y.; Toge, T.
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer
enhances their sensitivity to anticancer drugs. Int. J. Oncol. 2003,
22, 875-881.
(9) Garber, K. New apoptosis drugs face critical test. Nat. Biotechnol.
2005, 23, 409-411.
(10) Reed, J. C. Bcl-2 family proteins. Oncogene 1998, 17, 3225-3236.
(11) Adams, J. M.; Cory, S. Life-or-death decisions by the Bcl-2 protein
family. Trends Biochem. Sci. 2001, 26, 61-66.
(12) Zo¨rnig, M.; Hueber, A.; Baum, W.; Evan, G. Apoptosis regulators
and their role in tumorigenesis. Biochim. Biophys. Acta 2001, 1551,
F1-F37.
(13) Reed, J. C. Apoptosis-based therapies. Nat. ReV. Drug DiscoVery
2002, 1, 111-121.
(14) Sattler, M.; Liang, H.; Nettesheim, D. N.; Meadows, R. P.; Harlan,
J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn,
A. J.; Thompson, C. B.; Fesik, S. W. Structure of Bcl-xL-Bak peptide
complex: recognition between regulators of apoptosis. Science 1997,
275, 983-986.
(15) Holinger, E. P.; Chittenden, T.; Lutz, R. J. Bak BH3 peptides
antagonize Bcl-xL function and induce apoptosis through cytochrome
c-independent activation of caspases. J. Biol. Chem. 1999, 274,
13298-13304.
(16) Wang, J.; Liu, D.; Zhang, Z.; Shan, S.; Han, X.; Srinivasula, S. M.;
Croce, C. M.; Alnemri, E. S.; Huang, Z. Structure-based discovery
of an organic compound that binds Bcl-2 protein and induces
apoptosis of tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97,
7124-7129.
(17) Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.;
Mitchison, T.; Yuan, J. Identification of small-molecule inhibitors
of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol.
2001, 3, 173-182.
(35) Sinicrope, S. A.; Penington, R. C. Sulindac sulfide-induced apoptosis
is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in
human colon cancer cells overexpressing Bcl-2. Mol. Cancer Ther.
2005, 4, 1475-1483.
(18) Tzung, S.; Kim, K. M.; Basan´ez, G.; Giedt, C. D.; Simon, J.;
Zimmerberg, J.; Zhang, K. Y. J.; Hockenbery, D. M. Antimycin A
mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell
Biol. 2001, 3, 183-191.